PPARγ, PTEN, and the Fight against Cancer
2008

PPARγ, PTEN, and the Fight against Cancer

publication Evidence: moderate

Author Information

Author(s): Teresi Rosemary E., Waite Kristin A.

Primary Institution: Cleveland Clinic Foundation

Hypothesis

Can PPARγ act as a tumor suppressor by regulating PTEN in cancer development?

Conclusion

PPARγ agonists can induce functional PTEN protein that controls cellular growth and may inhibit tumor progression.

Supporting Evidence

  • PPARγ can regulate the transcription of PTEN, a known tumor suppressor.
  • Activation of PPARγ through agonists increases functional PTEN protein levels.
  • Genetic alterations of PPARγ can promote tumor progression.
  • PPARγ agonists have shown beneficial effects in cancer settings.

Takeaway

This study shows that a protein called PPARγ can help another protein, PTEN, fight cancer by stopping cells from growing too much.

Methodology

The study reviews in vitro and in vivo research on the relationship between PPARγ and PTEN in cancer.

Potential Biases

Potential bias due to the limited number of cancer types studied and reliance on specific PPARγ agonists.

Limitations

Most studies were performed in vitro, and the in vivo effects of PPARγ on PTEN in cancer are still being explored.

Digital Object Identifier (DOI)

10.1155/2008/932632

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication